General Information of Drug (ID: DMHB6UY)

Drug Name
S-9947 Drug Info
Synonyms
S9947; CHEMBL148159; AC1LCVHN; CHEBI:34965; 2'-(Benzyloxycarbonylaminomethyl)biphenyl-2-carboxylic acid 2-(2-pyridyl)ethylamide; SureCN498662; S-9947; SCHEMBL498662; GTPL2562; FLOLVFLAXFXKBU-UHFFFAOYSA-N; MolPort-042-665-732; CHEBI:342860; ZINC1491423; BDBM50123508; NCGC00386602-01; C13771; benzyl N-[[2-[2-(2-pyridin-2-ylethylcarbamoyl)phenyl]phenyl]methyl]carbamate; benzyl N-[[2-[2-[2-(2-pyridyl)ethylcarbamoyl]phenyl]phenyl]methyl]carbamate; [2''-(2-Pyridin-2-yl-ethylcarbamoyl)-biphenyl-2-ylmethyl]-carbamic acid benzyl este
Indication
Disease Entry ICD 11 Status REF
Atrial fibrillation BC81.3 Investigative [1]
Cross-matching ID
PubChem CID
656730
ChEBI ID
CHEBI:34965
TTD Drug ID
DMHB6UY

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Preclinical Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dronedarone DMA8FS5 Angina pectoris BA40 Approved [2]
BMS-919373 DMN28WK Atrial fibrillation BC81.3 Phase 2 [3]
IQB-9302 DMET0H4 Pain MG30-MG3Z Phase 1 [4]
XEN-D0103 DMR0U4V Atrial fibrillation BC81.3 Phase 1 [5]
BMS-394136 DMGDJQR Arrhythmia BC9Z Phase 1 [6]
XEN-D0101 DMU0V45 Atrial fibrillation BC81.3 Phase 1 [7]
T-226296 DMJ6P9U Obesity 5B81 Preclinical [2]
Zatebradine DMNYKOT Angina pectoris BA40 Terminated [8]
[14C]TEA DM6SFYH Discovery agent N.A. Investigative [9]
4-(4-phenoxybutoxy)-7H-furo[3,2-g]chromen-7-one DMKMH5L Discovery agent N.A. Investigative [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Voltage-gated potassium channel Kv1.5 (KCNA5) TTW0CMT KCNA5_HUMAN Blocker [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2562).
2 New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22.
3 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035504)
4 Stereoselective effects of the enantiomers of a new local anaesthetic, IQB-9302, on a human cardiac potassium channel (Kv1.5). Br J Pharmacol. 2001 Jan;132(2):385-92.
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 542).
6 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
7 Human electrophysiological and pharmacological properties of XEN-D0101: a novel atrial-selective Kv1.5/IKur inhibitor. J Cardiovasc Pharmacol. 2013 May;61(5):408-15.
8 DOI: 10.1161/01.CIR.94.3.562
9 Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. Mol Pharmacol. 1994 Jun;45(6):1227-34.
10 Substituted N-{3-[(1,1-dioxido-1,2-benzothiazol-3-yl)(phenyl)amino]propyl}benzamide analogs as potent Kv1.3 ion channel blockers. Part 2. Bioorg Med Chem Lett. 2010 Dec 1;20(23):6989-92.